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Abstract
D-cycloserine (DCS) is only used with multi-drug resistant strains of tuberculosis because of serious
side-effects. DCS is known to inhibit cell wall biosynthesis, but the in vivo lethal target is still
unknown. We have applied NMR-based metabolomics combined with principal component analysis
to monitor the in vivo affect of DCS on M. smegmatis. Our analysis suggests DCS functions by
inhibiting multiple protein targets.
Keywords
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Introduction
Tuberculosis (TB) is a world-wide problem as indicated by 5.1 million new and relapsed cases
reported in 2005 with South East Asia and Africa accounting for 35% and 23% of these cases,
respectively.1, 2 The TB case rate has increased dramatically in the past decade due to the
HIV/AIDS epidemic.1, 3 The high success rate of TB infections has contributed to the
emergence of multi-resistant strains of Mycobacterium tuberculosis.4 These multi-drug
resistant tuberculosis strains (MDR-TB) are associated with high mortality (50-80%).5
Antibiotic resistance in M. tuberculosis primarily emerges because of inadequate treatments
or patient noncompliance6, 7, which select for strains with decreased susceptibility to a specific
drug.1, 8 Increased resistance to first line drugs9, such as isoniazid and rifampin, is creating a
serious health crisis that requires the development of novel drugs to control future outbreaks
of M. tuberculosis.10, 11
D-cycloserine (DCS) is a second line drug for tuberculosis that is primarily used with MDR-
TB.12, 13 Second line drugs, like DCS, tend to have higher toxicity. Serious side-effects
associated with DCS have included seizures and mental disorders (schizophrenia, depression,
suicidal tendencies). DCS agonist activity against the N-methyl-D-aspartate (NMDA)
receptors may contribute to these observed neural disorders.14 Nevertheless, the potent activity
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of DCS against MDR-TB makes this compound an attractive prototype for developing new
antitubercle drugs.
DCS is a cyclic analogue of D-alanine, which is an essential metabolite for peptidoglycan
synthesis.13, 15, 16 DCS has been shown to inhibit D-alanine racemase (Alr) and D-alanine-
D-alanine ligase (Ddl) activity in vitro.17, 18 Recent studies have shown that mutations leading
to the over production of Alr decrease the susceptibility of mycobacteria to DCS.19, 20
Similarly, an alr null mutant increases the susceptibility of mycobacteria to DCS, but
surprisingly bacterial viability is not dependent on D-alanine.21 Thus, the lethal cellular target
(s) of DCS is still undetermined, but since mycobacteria sensitivity to DCS depends on Alr
activity, this suggests Alr is still a potential in vivo target contributing to the overall effect of
DCS. Potentially, the therapeutic activity of DCS may require inhibiting multiple proteins.
Identifying the in vivo target(s) and the associated metabolic pathways affected by DCS will
provide better insight into the mechanism of DCS antitubercular activity.
The enzymes involved in peptidoglycan biosynthesis and D-alanine metabolism can serve as
targets to monitor the in vivo activity of DCS through changes in the metabolome.22 Any
change in the activity of these enzymes through mutations or drug activities will affect the
network of metabolites associated with the corresponding pathways.23-25 Thus, monitoring
changes in metabolite concentrations will reflect corresponding changes in protein activity
caused by DCS or other drug activity. Nuclear magnetic resonance (NMR) is routinely used
to monitor perturbations in the metabolome by collecting one dimensional (1D) 1H NMR
spectra of cell extracts followed by multivariate data analysis.26-28 Principal component
analysis (PCA) is routinely used to reduce the multivariate NMR data into a two dimensional
(2D) scores plot. Each successive component captures the largest residual variance within the
NMR spectral array, and is orthogonal to the previous components in the NMR spectra.29,
30 Each NMR spectrum is reduced to a single point in the 2D scores plot, where similar spectra
will cluster close together and metabolome variants will form distinct and separate clusters.
The aim of this study is to apply NMR based metabolomics to understand the in vivo drug
activity of DCS and to determine if D-alanine racemase is a target of DCS in nonpathogenic
Mycobacterium smegmatis, a model system for tuberculosis for highly conserved pathways.
The metabolome of wild type (mc2155)31, D-alanine racemase null mutant (TAM23)21,
TAM23 complemented with wild-type alr gene (TAM23 pTAMU3), D-alanine racemase over
producing and DCS resistant mutant (GPM14)19 and another DCS-resistant strain unrelated
to alr mutations (GPM16)19 in the presence and absence of DCS was analyzed using 1H NMR
and PCA.
Materials and methods
Analysis of colony morphology
M. smegmatis cultures were grown to saturation in MADC (OD600 of ∼1-2). Serial dilutions
were plated on MADC agar supplemented with 50 mM D-alanine or 75ug/mL DCS as indicated
and grown at 37°C. Digital images of representative colonies were taken with a Nikon CoolPix
8700 camera and processed for enhancement of brightness and contrast with GIMP v2.2.13
using the Retinex filter.
Preparation of NMR Metabolomic Samples
A total of 120 cultures of M. smegmatis samples were grown in the following 10 groups; (1)
mc2155 (wild type), (2) TAM23 (D-alanine racemase null mutant), (3) TAM23 pTAMU3
(TAM23 complemented with wild-type alr gene) (4) GPM16 (DCS resistant mutant), (5)
GPM14 (D-alanine racemase over producing mutant), (6) mc2155 with DCS, (7) TAM23 with
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DCS, (8) TAM23 pTAMU3 with DCS, (9) GPM16 with DCS and (10) GPM14 with DCS.
Each culture is grown at 37°C with shaking at 200 rpm in 50mL of Middlebrook 7H9 broth
(250mL flask) for 10-12 hours (OD600 = 0.6-1.0). Cultures were treated with 75 μg/ml DCS 2
hours before harvesting. Each culture was placed on ice for 5 minutes and then centrifuged for
10 minutes at 2,700 rpm. The cell pellets were washed twice with 30 ml of ice cold double
distilled water. The cell pellets were resuspended with 10 ml of double distilled water and
transferred to 30 ml Pyrex beakers. The cell pellets were then sonicated on a salt-ice water bath
with a Vibra Cell Model VC600 for 5 minutes in the presence of 30% (vol/vol) type A-5
alumina. The cells were centrifuged again for 30 minutes at 15,000 rpm, and the supernatant
was collected to remove any cell debris. The supernatant was transferred in 50 ml Corning
orange cap tubes and frozen in an EtOH-dry ice bath to store at -80° C until ready to be analyzed.
The supernatant was lyophilized and resuspended in 1.0 ml of 100% D2O containing 50 mM
phosphate buffer (uncorrected pH = 7.2) with 50μM 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid
sodium salt (TMSP). The samples were stirred and centrifuged, where a 500 μL portion of the
cell free extract was transferred to an NMR tube.
NMR Data Processing and Multivariate Data Analysis
The NMR spectra were collected on a Bruker 500 MHz Avance spectrometer equipped with
a triple-resonance, Z-axis gradient cryoprobe. A BACS-120 sample changer with Bruker Icon
software was used to automate the NMR data collection. 1H NMR spectra were collected with
a standard Bruker pulse sequence (zgpr), solvent presaturation, a sweep width of 5482.5 Hz,
32K data points at 298K. A total of 4 dummy scans and 512 scans were used to obtain each of
the NMR spectra. All peak positions were measured relative to the TMSP reference peak set
to 0.0 ppm.
The 8 groups of 10 (GPM14, GPM16, TAM23, TAM23 pTAMU3 with/without DCS) and 2
groups of 20 (mc2155 with/without DCS) NMR spectra were processed automatically using a
standard processing macro in the ACD/1D NMR manager version 8.0 (Advanced Chemistry
Development, Inc., Toronto, Ontario). The residual H2O NMR resonance between 4.48 and
5.11 ppm was set to 0 and excluded from bucketing and PCA analysis. The baseline was
corrected using spectrum averaging with a box half-width of 15 points and a noise factor of 2
to differentiate between real peaks and noise regions. Intelligent bucketing was used to integrate
each region with a bin size of 0.025 ppm with a width looseness of 50%. The table of integrals
was transferred to MS Excel, which was used to arrange all 120 samples based on the ten groups
described above. An Excel macro was then used to combine the NMR spectra into a single file
to normalize the binned intensities to a total integrated intensity of 1.0. The table was then
imported into SIMCA (UMETRICS, Kinnelon, NJ) for PCA analysis using the program's
standard parameters. Our previous analysis indicated that the presence of noise regions in the
bucketing of NMR spectra can result in large and irrelevant variations in the PCA
clustering32. Exclusion of the noise regions of the 1H NMR spectra was accomplished by an
Excel macro that set the value of every bin below a certain intensity threshold to zero. Regions
outside the spectral width of 0.0 ppm and 10.0 ppm and between 4.48 ppm to 5.11 ppm were
removed to eliminate any undesired variations.
Results and Discussion
Mycobacterium smegmatis metabolome model system
Peptidoglycan biosynthesis is a conserved biological process present in most eubacteria
including M. tuberculosis and M. smegmatis.33 Peptidoglycan forms the backbone of the lipid-
rich mycobacterial cell wall and functions as a barrier against most drugs.34 It also withstands
internal osmotic pressure and defines the cell shape.35 Peptidoglycan is formed via the
peptidoglycan biosynthesis pathway, where in mycobacteria each chain is composed of
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alternating N-acetylglucosamine (GlcNAc) and, N-glycolylmuramic or N-acetylmuramic acid
subunits.36 A pentapeptide is attached to each disaccharide unit at the muramic acid residue,
where the final two D-alanine side chain amino acids are attached as a dipeptide.37, 38 This
dipeptide participates in the cross-linking between peptidoglycan chains. Thus, the D-alanyl-
D-alanine dipeptide is an essential building block of the peptidoglycan chain and is formed as
part of the D-alanine pathway illustrated in Figure 1. D-alanine is a necessary precursor to the
dipeptide and is converted from naturally occurring L-alanine by the enzyme alanine racemase
(Alr).39, 40 The dipeptide is formed from the condensation of two D-alanine moieties by the
enzyme D-alanine-D-alanine ligase (Ddl).35, 37
The null mutant alr gene was used to generate the TAM23 M. smegmatis mutant strain where
D-alanine racemase is inactivated, eliminating a pathway for the conversion of L-alanine into
D-alanine.21 The alr gene has been found in many other bacterial species such as E. coli and
streptococcus species.40 Two alr genes have been identified in E. coli41, 42, where alr encodes
for biosynthesis activity and the dadX gene is involved in L-Ala catabolism.40, 42, 43 E.
coli cell growth is completely dependent on supplemental D-alanine when both D-alanine
racemase genes are inactivated.42, 43 Only one known alr gene is found in M. smegmatis.
DCS is effective against mycobacterium because it disrupts cell wall synthesis by inhibiting
peptidoglycan biosynthesis. DCS is known to inhibit both Alr and Ddl in a concentration
dependent manner.17, 18 However, over production of Alr contributes to DCS resistance
suggesting that Alr may be an additional non-lethal binding target of DCS (Table 1).
Nonetheless, Alr inhibition may contribute to the overall bactericidal effect as reflected by the
hypersusceptibility of TAM23 to DCS.16, 19 The Alr over producing mutant (GPM14) strain
and an unrelated DCS-resistant (GPM16) strain were identified from a group of M.
smegmatis mutants that occurred spontaneously.
M. smegmatis dependence on D-alanine for growth
D-alanine is a major component in cell wall synthesis and is essential for cell survivability.
38, 44 The production of D-alanine is a major component of the alanine pathway (Figure 1).
The effect of the presence of D-alanine in the culture medium on the growth of wild type M.
smegmatis (mc2155), the TAM23 null mutant and the TAM23 pTAMU3 alr complement
mutant was explored by examining the colony morphology for the three strains in both the
presence and absence of D-alanine (figure 2). Wild type M. smegmatis and the TAM23 and
TAM23 pTAMU3 mutants were grown in MADC agar supplemented with 50 mM D-alanine,
where a second culture of cells were grown without D-alanine. Similar cell cultures were
obtained for the two DCS resistant (GPM14, GPM16) strains.
If the only source of D-alanine for M. smegmatis is from the conversion of L-alanine by D-
alanine racemase, then the viability of the TAM23 null mutant should be completely dependent
on a supplemental source of D-alanine. Surprisingly, this is not the case.21 Wild-type M.
smegmatis, TAM23 pTAMU3, DCS resistant strains (GPM14, GPM16) and TAM23 are able
to grow both in the presence (Figure 2 B, E, H, K, N) and the absence of D-alanine (Figure 2
A, D, G, J, M). However, the growth is slower in the absence of D-alanine, where the cell wall
of TAM23 appears to be weaker by its flaky appearance and irregular shaped borders. The
ability for TAM23 to grow in the absence of D-alanine signifies that a secondary pathway for
the production of D-alanine must be present, but the weaker appearance of the cell wall shows
that the Alr is the primary enzyme for the production of D-alanine in M. smegmatis.
Effect of DCS on M. smegmatis colony morphology
As an indication of the DCS effect on the wild type and mutant strains, we determined colony
morphologies of cells grown with DCS (Figure 2 C, F, I, L). As controls, cells were also grown
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in regular medium with and without D-alanine. Cells were grown in MADC broth to saturation,
diluted and plated on MADC agar until colonies reached an appropriate size. M. smegmatis
wild type, TAM23 pTAMU3, and DCS resistant strains had similar colony morphotypes
regardless of the presence of D-alanine or DCS. The yellowish colonies displayed a rough and
waxy appearance with irregular and lobate margins. However, the DCS hypersusceptible strain
TAM23, on MADC medium lacking D-alanine, displayed colonies with a dryer and flatter
appearance, and more smooth margins, as previously described.32 Addition of D-alanine
partially restored the wild type morphotype, while DCS greatly exacerbated the colony
morphology alterations yielding smooth flattened colonies. The effects of D-alanine and DCS
on the TAM23 mutant directly correlate with the NMR metabolomic studies described below.
NMR spectral changes
The concentration of the metabolites in M. smegmatis cell extracts are directly related to peak
intensities in the NMR spectra. Mutations or drugs that inhibit a particular enzyme will cause
changes in NMR peak intensities pertaining to the affected metabolites. Detailed analysis of
NMR spectral changes is possible because of recent efforts to compile metabolomic databases
that incorporate detailed NMR assignment information.45-47 This includes the human
metabolome database (http://www.hmdb.ca/scripts/Biofluid_browse.cgi), the Madison
metabolomics consortium database (http://mmcd.nmrfam.wisc.edu/) and the NMR
metabolomics database (http://www.liu.se/hu/mdl/main/). Characterization of the chemical
composition of the metabolome and the availability of related NMR data is still incomplete,
but the relative comparative difference between NMR spectra still provides some valuable
insights. The NMR spectra from wild-type (mc2155) and TAM23 M. smegmatis mutant cells
in the presence and absence of DCS are shown in Figure 3.
The NMR spectrum of TAM23 cell extracts indicate that alanine (1.43 ppm) and UDP (5.50,
6.0 and 8.0 ppm) concentrations have increased, where these peak are absent in the wild-type
spectrum. An increase in UDP would be expected from a stalled or disrupted peptidoglycan
synthesis. Similarly, the concentration of D-alanine and L-alanine are expected to change when
comparing the wild-type (mc2155) and TAM23 metabolome. Unfortunately, both these
metabolites exhibit identical chemical shifts and are not differentiated in the NMR spectra of
cell lysates.
Also, glutamate (2.10 and 2.33 ppm) concentration appears to be decreased by the inactivation
of Alr in the TAM23 mutant. The region of the NMR spectrum that includes the glutamate
peaks shows a distinct decrease in intensity between the wild type and TAM23 mutant cells.
Since glutamate metabolism is an important precursor to peptidoglycan synthesis, this may
suggest a second D-alanine synthesis pathway is active in TAM23 cells. The glutamate and
alanine metabolism pathways are connected by the intervening pyrimidine metabolism
pathway. Potentially, glutamate may become a source of D-alanine through a pyrimidine
metabolism pathway that can produce D-alanine instead of L-alanine.
There also appears to be a dramatic decrease in the concentration of formate (8.46 ppm), a
product of pyruvate metabolism in the formation of acetyl-CoA. Instead of producing acetyl-
CoA, pyruvate may also be used with glutamate to produce D-alanine through a mechanism
separate from the pyrimidine metabolism pathway. This may occur through the activity of D-
alanine aminotransferase, which catalyzes the formation of D-alanine through a reaction that
utilizes pyruvate and D-glutamate. It is important to note that while this enzyme has been
identified in a number of bacterial genomes, it has not been identified in M. smegmatis.
Glutamate racemase would convert L-glutamate to D-glutamate. An additional product of this
reaction is 2-oxoglutarate, which is a metabolite in the tricarboxylic acid cycle (TCA). The
TCA cycle connects with the nicotinate and nicotinamide metabolism pathways, which may
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also explain why these metabolites exhibit an increase in concentration with the addition of
DCS.
These potential alternate D-alanine synthesis pathways implies that TAM23 does not simply
contain a second D-alanine racemase, but that D-alanine must be synthesized through a second
unique mechanism. This is consistent with the previous observations that alr null mutants do
not exhibit D-alanine racemase activity.21 It is also consistent with the analysis of the cell
morphology of TAM23 that indicates viable cells with weak cell walls in the absence of D-
alanine.
The impact of DCS on the NMR spectra of TAM23 and wild-type M. smegmatis cells is even
more dramatic than the difference between the TAM23 and wild-type cell strains. NMR peaks
in the amino-sugar region (4.0-4.5 ppm), riboside region (5.0-6.5 ppm), and nucleoside region
(7.75-8.75 ppm) exhibit the most significant changes in the drug treated culture. The amino-
sugars identified are UDP-N-acetyl-D-glucosamine, UDP-N-acetylmuramate, N-acetyl-D-
mannosamine, as well as other D-glucosamine and muramate groups. These amino-sugars are
used as building blocks to help initiate the peptidoglycan synthesis. The amino-sugars
concentrations are increased due to inadequate amounts of D-alanine required to form
peptidoglycan chains. Thus, these metabolites result from failed peptidoglycan synthesis
caused by enzymes inhibited by DCS.
Analysis of other NMR spectral changes due to the addition of DCS indicates an increase in
nicotinate (8.61 ppm), NAD (7.85, 8.13, and 8.22 ppm), nicotinimide D-ribonucleotide (6.15
ppm). The concentration of UDP and CDP (5.95 and 6.14 ppm) are also increased in the
presence of DCS, which accounts for the increased concentrations of UDP bound amino-
sugars. These metabolites are associated with nicotinate and nicotinamide metabolism and
pyrimidine metabolism. The increase in the concentrations of metabolites associated with the
pyrimidine metabolism pathway is consistent with DCS activity because of the interconnection
of the alanine metabolism and pyrimidine metabolism pathways. A similar relationship exists
between the alanine metabolism and nicotinate and nicotinamide metabolism.
PCA of DCS activity in M. smegmatis
PCA analysis of the NMR metabolomic data provides an unbiased approach to determine an
overall similarity between the various cell cultures. The complete set of 120 NMR spectra was
analyzed using PCA, which reduces each individual spectrum to a single point in a 2D scores
plot (Figure 4). The position of each point (spectrum) is based on the relative peak variations
(metabolites) between each spectrum. NMR spectra of cell extracts with similar metabolite
composition and concentrations will cluster close together in the 2D scores plot. Conversely,
NMR spectra of cell extracts with variable metabolite composition and concentrations will
form distinct clusters.
The 2D scores plot comparing each of the 120 NMR spectra using the two largest variations
is shown in Figure 3. PC1 accounts for 37.5% of the variation between the spectra and PC2
accounts for an additional 9.7% of the variation. Three distinct clusters are readily apparent in
the 2D scores plot. As expected, the wild-type M. smegmatis (mc2155) cells form a distinct
and separate cluster from the alr null mutant (TAM23) cells. This is consistent with the
inactivation of the D-alanine racemase, the corresponding impact on the metabolome for the
TAM23 mutant and the detailed changes in the NMR spectra described above. Also as
expected, the TAM23 pTAMU3 complement mutant clusters with wild-type (mc2155) cells
since Alr activity has been restored. This clearly indicates that the distinct PCA clustering
observed between wild-type and TAM23 cells is primarily caused by a difference in Alr
activity. Surprisingly, the unrelated DCS resistant strain (GPM16) forms a broad cluster that
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overlaps with wild-type M. smegmatis. Thus, the mutation in GPM16 appears to have a minimal
impact on the M. smegmatis metabolome relative to the D-alanine racemase null mutant.
Conversely, the close clustering between wild-type M. smegmatis and the Alr over producing
mutant (GPM14) is not surprising since there was neither a loss nor gain of an enzymatic
function. The increased level of Alr does not impact the metabolome probably because Ddl is
a more efficient enzyme than Alr48, 49. Any increase in D-alanine would be transitory and
rapidly converted to D-alanyl-D-alanine dipeptide.
The PCA of the M. smegmatis cell strains in the presence of DCS yielded interesting results.
If the primary target of DCS is alanine racemase, then wild-type cells in the addition of DCS
would have clustered with TAM23 in both the presence and absence of DCS. DCS would
simply inhibit the activity of Alr and mimic TAM23, an alr null mutant. Moreover, if Alr is
the sole lethal target, it would have required us to isolate a conditional rather than a null mutant
to describe the metabolome associated with an Alr-deficient strain. Also, DCS would not
induce any further changes in the TAM23 metabolome. This was not the case as evident by
the large changes in the NMR spectra caused by the addition of DCS as seen in Figure 3. First,
the 2D scores plot indicate that TAM23 with the addition of DCS forms a distinct cluster from
TAM23 in the absence of DCS. This clearly indicates that DCS is inhibiting a second protein
target besides Alr. Second, the wild-type cells with the addition of DCS also clustered closely
with TAM23 in the presence of DCS. This establishes that Alr is also targeted by DCS. These
results indicate that DCS is targeting multiple protein targets consistent with enzyme data
demonstrating an inhibitory affect on both Alr and Ddl.17, 18
An unexpected result was the observation that the GPM14 and GPM16 DCS resistant mutants
also clustered together with TAM23 and wild-type cells in the presence of DCS. This clearly
indicates that the lethal target(s) for DCS is still inhibited in the resistant strains and that the
over production of Alr in GPM14 or the unrelated mutation in GPM16 simply compensate for
the inhibition of the DCS lethal target.
Is D-alanine-D-alanine ligase the primary lethal target of DCS? Our data clearly indicates that
Alr is not the primary lethal target of DCS. Wild-type cells in the presence of DCS do not
cluster with the alr null mutant cells (TAM23). Furthermore, all the cell cultures in the presence
of DCS form a separate and distinct cluster from TAM23 in the absence of DCS. This would
only occur if DCS is inhibiting a second protein besides Alr that results in further changes in
the metabolome. This is clearly apparent when individual NMR spectra are compared with and
without the addition of DCS. On a relative scale, smaller changes in the NMR spectra are
observed when comparing wild-type and TAM23 cells. This is consistent with the simple
induction of a secondary pathway in TAM23 to generate the essential D-alanine required for
peptidoglycan synthesis, not a dramatic change that would be expected from a lethal inhibition
of cell wall synthesis. These NMR results are also consistent with the observation that the
alr null mutants is viable in the absence of D-alanine. Inactivating both D-alanine racemase
genes in E. coli resulted in cell growth being completely dependent on supplemental D-alanine.
42, 43
It is plausible that DCS is broadly active and inhibits multiple proteins involved in cell wall
synthesis to result in cell death. Comparison of the NMR spectra for wild-type and TAM23
cells in the presence of DCS indicate that the difference in the metabolome caused by the alr
null mutant is still present. Since this difference is attributed to the induction of a second D-
alanine synthetic pathway, this pathway does not appear to be induced in wild-type cells from
the addition of DCS. This also suggests that the inhibition of Alr in wild-type cells is not severe
enough to induce this second pathway or that this second pathway is still active in TAM23
cells. Since the alr null mutation in TAM23 cells is not sufficient to induce cell death and the
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appearance that DCS is not inhibiting the secondary D-alanine synthetic pathway, DCS is
probably acting through another primary lethal target besides Alr. These results are also
consistent with the observation that TAM23 cells are more susceptible to DCS (Table 1). Cell
morphology indicates that the TAM23 cell walls are weak with flaky and irregular shape. This
implies that the second pathway for D-alanine synthesis is a poor substitute for the Alr pathway,
and thus, cell death may occur before a complete inhibition of the primary lethal target of DCS
occurs.
The NMR metabolomics data indicate that the DCS resistant mutant cells also cluster with
wild-type and TAM23 cells in the presence of DCS. This indicates that the DCS resistant cells
do not eliminate the impact of DCS on the metabolome, but simply alleviate the cell damage.
DCS is still inhibiting enzymes in the cell wall synthetic pathway, but it is no longer capable
of preventing cell wall synthesis. D-alanine-D-alanine ligase needs to bind two D-alanine
molecules prior to forming the essential D-alanyl-D-alanine dipeptide. Presumably, DCS could
compete with either D-alanine binding site to inhibit Ddl activity. Similarly, since DCS has
been shown to efficiently inhibit Ddl, this enzyme appears a likely candidate for the primary
lethal target of DCS. Increasing the cellular concentration of D-alanine, as it was shown to
occur in GPM14,16 would enable it to compete with DCS and allow for the production of the
D-alanyl-D-alanine dipeptide.
Why isn't Ddl simply overproduced to reduce the bacteria's susceptibility to DCS? The activity
of D-alanine racemase is modulated by the induction of L-alanine dehydrogenase, which
provides the cell with a mechanism to minimize any negative impact from overproducing Alr.
50 A similar feed-back mechanism is not known to exist for Ddl. Similarly, D-alanine and L-
alanine are ubiquitous metabolites with multiple uses in the cell. Conversely, the D-alanyl-D-
alanine dipeptide is an essential end-product that may not be as well-tolerated if overproduced
due to a mutation leading to high levels of Ddl over-productions. In this context, overproduction
of Ddl in M. smegmatis from a recombinant plasmid leads to a lower level of resistance to ddl.
Therefore, overproducing Ddl may not be the most efficient means to protect mycobacteria
from DCS. Thus, the lethal action of DCS may act through the inhibition of Ddl while resistance
to DCS is mediated by the overproduction of Alr.
Conclusion
A comparative metabolic study of the activity of DCS in M. smegmatis was conducted by
Principal Component Analysis and NMR spectroscopy. The metabolome of wild type
(mc2155), alr null mutant (TAM23), TAM23 complemented with wild-type alr gene (TAM23
pTAMU3) and DCS resistant mutants (GPM14, GPM16) were monitored to investigate the
mechanism of action of DCS. Differences in the NMR spectra between wild-type and TAM23
cells suggest the presence of a second D-alanine synthetic pathway in the alr null mutant. This
is consistent with the viability of the TAM23 cells in the absence of supplemental D-alanine.
This secondary pathway appears to still be present in the TAM23 cells, but not induced in wild-
type cells when both wild-type and TAM23 cells are exposed to DCS. This is consistent with
the PCA results that indicate TAM23 and wild-type cells form separate and distinct clusters,
but all five strains cluster together in the presence of DCS.
These results are consistent with multiple DCS targets that include Alr and Ddl in the
peptidoglycan biosynthetic pathway. The clustering of the DCS resistant cells with wild-type
and TAM23 cells indicate that DCS is still active and inhibiting cell wall pathway enzymes,
but the detrimental impact has been minimized. Thus, D-alanine-D-alanine ligase appears to
be the lethal target of DCS. This hypothesis is consistent with: (i) DCS resistant mutants that
overproduce Alr, (ii) Alr is not a lethal target, (iii) secondary D-alanine pathway is unaffected
by DCS, and (iv) DCS efficiently inhibits biosynthesis of D-alanine-D-alanine. It appears that
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the overproduction of Alr simply increases the efficiency by which D-alanine can compete
with DCS to enable the production of the essential D-alanyl-D-alanine dipeptide.
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Figure 1.
Alanine racemase converts L-alanine to D-alanine in the alanine pathway. D-alanyl-D-alanine
ligase binds two molecules of D-alanine by peptide bonds, which is then used in the
peptidoglycan biosynthesis pathway to form the cell wall.
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Figure 2.
Wild type mc2155 (A-C) and mutants GPM 14 (D-F), GPM 16 (G-I), TAM 23 (J-L), and
TAM23 pTAMU3 (M-O) cells were plated on MADC (A,D,G,J), MADC with 50 mM D-
alanine (B,E,H,K), MADC with 50 μg/ml DCS (C,F,I), or MADC with 1.73 μg/ml DCS (L).
Plates were incubated at 37°C until colony diameters were c.a. 1.0 cm and colony images were
digitally captured, cropped, and scaled to similar sizes. Each picture has a scale bar (5.0 mm)
to indicate the actual colony size.
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Figure 3.
1D 1H NMR spectra in order from bottom to top are: TAM23, mc2155, TAM23 with DCS,
and mc2155 with DCS.
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Figure 4.
PCA scores plot comparing mc2155 ( ), TAM23 (●), GPM14 ( ), GPM16 ( ),TAM23
pTAMU3 ( ) mc2155 with DCS ( ), and TAM23 with DCS ( ), GPM14 with DCS ( ),
GPM16 with DCS ( ), and TAM23 pTAMU3 with DCS ( ).
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Table 1
Summary of M. smegmatis cell strains and the minimal inhibitory concentration (MIC) used in the NMR metabolomics
study.
M. smegmatis Strain Relevant Characteristics MIC DCS
(μg/ml)
Reference
mc2155 Alr+; high efficiency plasmid transformation mutant of mc26 75.0 Snapper et al. (1990)31
GPM14 First-step DCSr spontaneous mutant derived from mc2155;
overproduces D-alanine racemase
300 Caceres et al. (1997)19 & Feng
et al. (2003)16
GPM16 First-step DCSr spontaneous mutant derived from mc2155 150 Caceres et al. (1997)19
TAM23 Alr- Kanr; M. smegmatis alr mutant derived from mc2155 2.56 Chacon et al. (2002)21
TAM23 pTAMU3 Alr+ Hygr Kanr; M. smegmatis alr mutant complemented with
wild-type gene integrated at the mycobacteriophage L5 attB site
75.0 Chacon et al. (2002)21
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